journal logo
  • search
  • open the menu

Intro Pullout Text Widget

The Journal for ImmunoTherapy of Cancer

is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.

Impact Factor: 12.469
Citescore: 14.3
All metrics >>

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

JITC is the official journal of the Society for Immunotherapy of Cancer (SITC).

EDITOR-IN-CHIEF
Pedro J. Romero, MD, University of Lausanne
Editorial Board

Current Issue

Highlighted Articles

Highlighted Articles

Authors

The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.

The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.

Information is also provided on editorial policy, Open Access fees and formatting.

Twitter Feed

Altmetrics

What Our Editors Are Reading

In JITC’s Reading List, JITC editors provide a monthly list of publications in other journals that have their attention and add value to what readers may find in JITC. Read what has piqued the interest of this month’s featured editor, Dr. Marcela Maus, Section Editor for the Immune Cell Therapies and Immune Cell Engineering Section, in the latest Reading List.

 

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

 

Explore SITC’s cancer immunotherapy community at sitcancer.org and become a member to take advantage of SITC’s member benefit of 50% off APCs for all articles submitted and accepted in JITC in 2022.